Xinqi Wu
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, Immunotherapy and Immune Responses, Cutaneous Melanoma Detection and Management, CAR-T cell therapy research
Most-Cited Works
- → Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma(2014)601 cited
- → Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade(2017)358 cited
- → Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS)(2001)331 cited
- → Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy(2016)161 cited
- → Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab(2014)140 cited
- → A TB-RBP and Ter ATPase Complex Accompanies Specific mRNAs from Nuclei through the Nuclear Pores and into Intercellular Bridges in Mouse Male Germ Cells(2002)96 cited
- → The RNA-binding protein, TB-RBP, is the mouse homologue of translin, a recombination protein associated with chromosomal translocations(1997)87 cited
- → VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma(2016)87 cited
- → The long extra arms of human tRNA(Ser)Secand tRNASerfunction as major identity elements for serylation in an orientation-dependent, but not sequence-specific manner(1993)86 cited
- → Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-κB Pathways(2012)86 cited